PharmaCyte Biotech, Inc. (PMCB)
About PharmaCyte Biotech, Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- $30.7M
- Total assets
- $55.2M
- Market cap
- $7.5M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $4.4M
- Operating income
- -$4.4M
- Income tax
- $0
- Net income
- $30.7M
- EPS (basic)
- $3.19
- EPS (diluted)
- $3.19
Balance sheet
- Total assets
- $55.2M
- Current assets
- $22.4M
- Total liabilities
- $3.3M
- Current liabilities
- $2.9M
- Shareholders’ equity
- $51.9M
Cash flow
- Operating cash flow
- -$3.0M
- Investing cash flow
- -$7.0M
- Financing cash flow
- -$25.0M
- Net cash flow
- -$35.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $7.5M
- P/E ratio
- 0.2
- EPS (diluted)
- $3.19
- Shares outstanding
- 12.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 11, 2003
PharmaCyte Biotech, Inc. (PMCB) Stock Price
- Profitable — net income of $30.7M in FY2025.
- Trading 51% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 0.2.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review PharmaCyte Biotech, Inc..
Write a review
News about PharmaCyte Biotech, Inc.
News & sentiment via Polygon.io
PharmaCyte Biotech, Inc.: frequently asked questions
Is PharmaCyte Biotech, Inc. an American company?
PharmaCyte Biotech, Inc. is a US-based company headquartered in Las Vegas, Nevada, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is PharmaCyte Biotech, Inc. headquartered?
PharmaCyte Biotech, Inc. is headquartered in Las Vegas, Nevada, United States.
Is PharmaCyte Biotech, Inc. publicly traded?
Yes — PharmaCyte Biotech, Inc. is a publicly traded company. Its stock trades under the ticker symbol PMCB on the NASDAQ.
What does PharmaCyte Biotech, Inc. do?
PharmaCyte Biotech, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
